Cargando…
Modified Cap-Assisted Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Rectal Neuroendocrine Tumors ≤10 mm: A Randomized Noninferiority Trial
INTRODUCTION: Although recent guidelines recommend endoscopic resection of rectal neuroendocrine tumors (NET) ≤10 mm, there is no consensus on which endoscopic modality should be performed. We aimed to compare the safety and efficacy of modified cap-assisted endoscopic mucosal resection (mEMR-C) and...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508268/ https://www.ncbi.nlm.nih.gov/pubmed/36455222 http://dx.doi.org/10.14309/ajg.0000000000001914 |
_version_ | 1785107497681420288 |
---|---|
author | Gao, Xuelian Huang, Shaohui Wang, Yusi Peng, Qun Li, Weixin Zou, Yingying Han, Zelong Cai, Jianqun Luo, Yuchen Ye, Yaping Li, Aimin Bai, Yang Chen, Ye Liu, Side Li, Yue |
author_facet | Gao, Xuelian Huang, Shaohui Wang, Yusi Peng, Qun Li, Weixin Zou, Yingying Han, Zelong Cai, Jianqun Luo, Yuchen Ye, Yaping Li, Aimin Bai, Yang Chen, Ye Liu, Side Li, Yue |
author_sort | Gao, Xuelian |
collection | PubMed |
description | INTRODUCTION: Although recent guidelines recommend endoscopic resection of rectal neuroendocrine tumors (NET) ≤10 mm, there is no consensus on which endoscopic modality should be performed. We aimed to compare the safety and efficacy of modified cap-assisted endoscopic mucosal resection (mEMR-C) and endoscopic submucosal dissection (ESD) methods for the treatment of rectal NET ≤10 mm. METHODS: A randomized noninferiority trial comparing mEMR-C and ESD was conducted. The primary outcome was the histological complete resection rate; the secondary outcomes included en bloc resection rate, operation time, complications, and so on. Subgroup analyses and follow-up were also performed. RESULTS: Ninety patients were enrolled, and 79 patients with pathologically confirmed rectal NET were finally analyzed, including 38 cases of mEMR-C and 41 cases of ESD. Histological complete resection rate was 97.4% in the mEMR-C group and 92.7% in the ESD group. The noninferiority of mEMR-C compared with that of ESD was confirmed because the absolute difference was 4.7% (2-sided 90% confidence interval, −3.3% to 12.2%; P = 0.616). En bloc resection and successful removal of rectal NET were achieved in all patients. Advantages of mEMR-C over ESD included shorter operation time (8.89 ± 4.58 vs 24.8 ± 9.14 minutes, P < 0.05) and lower hospitalization cost ($2,233.76 ± $717.70 vs $2,987.27 ± $871.81, P < 0.05). Postoperative complications were recorded in 4 patients who received mEMR-C and 2 patients in the ESD group (11.5% vs 4.9%, P = 0.509), which were all well managed using endoscopy. Similar findings were observed when subgroup analysis was performed. DISCUSSION: mEMR-C is noninferior to ESD with a similar complete resection rate. In addition, mEMR-C had shorter procedure duration time and lower hospitalization costs. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03982264. |
format | Online Article Text |
id | pubmed-10508268 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer |
record_format | MEDLINE/PubMed |
spelling | pubmed-105082682023-09-20 Modified Cap-Assisted Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Rectal Neuroendocrine Tumors ≤10 mm: A Randomized Noninferiority Trial Gao, Xuelian Huang, Shaohui Wang, Yusi Peng, Qun Li, Weixin Zou, Yingying Han, Zelong Cai, Jianqun Luo, Yuchen Ye, Yaping Li, Aimin Bai, Yang Chen, Ye Liu, Side Li, Yue Am J Gastroenterol Article INTRODUCTION: Although recent guidelines recommend endoscopic resection of rectal neuroendocrine tumors (NET) ≤10 mm, there is no consensus on which endoscopic modality should be performed. We aimed to compare the safety and efficacy of modified cap-assisted endoscopic mucosal resection (mEMR-C) and endoscopic submucosal dissection (ESD) methods for the treatment of rectal NET ≤10 mm. METHODS: A randomized noninferiority trial comparing mEMR-C and ESD was conducted. The primary outcome was the histological complete resection rate; the secondary outcomes included en bloc resection rate, operation time, complications, and so on. Subgroup analyses and follow-up were also performed. RESULTS: Ninety patients were enrolled, and 79 patients with pathologically confirmed rectal NET were finally analyzed, including 38 cases of mEMR-C and 41 cases of ESD. Histological complete resection rate was 97.4% in the mEMR-C group and 92.7% in the ESD group. The noninferiority of mEMR-C compared with that of ESD was confirmed because the absolute difference was 4.7% (2-sided 90% confidence interval, −3.3% to 12.2%; P = 0.616). En bloc resection and successful removal of rectal NET were achieved in all patients. Advantages of mEMR-C over ESD included shorter operation time (8.89 ± 4.58 vs 24.8 ± 9.14 minutes, P < 0.05) and lower hospitalization cost ($2,233.76 ± $717.70 vs $2,987.27 ± $871.81, P < 0.05). Postoperative complications were recorded in 4 patients who received mEMR-C and 2 patients in the ESD group (11.5% vs 4.9%, P = 0.509), which were all well managed using endoscopy. Similar findings were observed when subgroup analysis was performed. DISCUSSION: mEMR-C is noninferior to ESD with a similar complete resection rate. In addition, mEMR-C had shorter procedure duration time and lower hospitalization costs. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03982264. Wolters Kluwer 2022-12 2022-08-23 /pmc/articles/PMC10508268/ /pubmed/36455222 http://dx.doi.org/10.14309/ajg.0000000000001914 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Gao, Xuelian Huang, Shaohui Wang, Yusi Peng, Qun Li, Weixin Zou, Yingying Han, Zelong Cai, Jianqun Luo, Yuchen Ye, Yaping Li, Aimin Bai, Yang Chen, Ye Liu, Side Li, Yue Modified Cap-Assisted Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Rectal Neuroendocrine Tumors ≤10 mm: A Randomized Noninferiority Trial |
title | Modified Cap-Assisted Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Rectal Neuroendocrine Tumors ≤10 mm: A Randomized Noninferiority Trial |
title_full | Modified Cap-Assisted Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Rectal Neuroendocrine Tumors ≤10 mm: A Randomized Noninferiority Trial |
title_fullStr | Modified Cap-Assisted Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Rectal Neuroendocrine Tumors ≤10 mm: A Randomized Noninferiority Trial |
title_full_unstemmed | Modified Cap-Assisted Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Rectal Neuroendocrine Tumors ≤10 mm: A Randomized Noninferiority Trial |
title_short | Modified Cap-Assisted Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Rectal Neuroendocrine Tumors ≤10 mm: A Randomized Noninferiority Trial |
title_sort | modified cap-assisted endoscopic mucosal resection versus endoscopic submucosal dissection for the treatment of rectal neuroendocrine tumors ≤10 mm: a randomized noninferiority trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508268/ https://www.ncbi.nlm.nih.gov/pubmed/36455222 http://dx.doi.org/10.14309/ajg.0000000000001914 |
work_keys_str_mv | AT gaoxuelian modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial AT huangshaohui modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial AT wangyusi modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial AT pengqun modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial AT liweixin modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial AT zouyingying modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial AT hanzelong modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial AT caijianqun modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial AT luoyuchen modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial AT yeyaping modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial AT liaimin modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial AT baiyang modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial AT chenye modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial AT liuside modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial AT liyue modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial |